Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 20
Filtrar
Mais filtros












Base de dados
Intervalo de ano de publicação
2.
Gynecol Oncol ; 157(1): 85-88, 2020 04.
Artigo em Inglês | MEDLINE | ID: mdl-31954531

RESUMO

OBJECTIVE: To evaluate the role of laparoscopic (LPS) and laparotomic (LPT) re-staging in patients with incompletely surgically staged ovarian granulosa cell tumors (OGCT). METHODS: We conducted a medical chart retrospective analysis of all patients with sex cord stromal tumors (SCSTs) who were managed in our division between March 1994 and March 2017. After a complete review of surgical and pathological notes, patients with incomplete staging were restaged according to the FIGO guidelines. Statistical analysis was conducted using Statistical Package version 20.0 for Windows (SPSS, Inc., Chicago, Illinois). RESULTS: Out of a total of 170 patients SCSTs, 84 patients (49,5%) received primary surgery that included a hysterectomy; 86 patients (50,5%) underwent fertility-sparing surgery. Eighty-one patients (48%) with diagnosis of OGCT were incompletely surgically staged at another institution. We evaluated our results in terms of laparoscopic approach (56 patients) and open treatment (25 patients). Among the IA patient's group, 1 was upstaged to IIB stage and 2 to IIIB; among patients with IC stage, 1 was upstaged to IIA, 2 to IIB and 1 to IIIB stage. Adjuvant chemotherapy was given to the upstaged patients with final stage IIB-IIIC. No statistically significant difference between laparoscopy and open-surgery was detected in terms of upstaged patients after second surgery (p = 0,36). CONCLUSION: According to our series, laparoscopic restaging compared to the open approach seems to be a feasible and efficient technique to complete surgical staging in patients with GCTs incorrectly staged. Surgical restaging seems to upstage a considerable number of OGCT, mainly in the initial stage IC group of patients. However, the impact of restaging on final outcome and survival remains to be demonstrated.


Assuntos
Tumor de Células da Granulosa/patologia , Tumor de Células da Granulosa/cirurgia , Neoplasias Ovarianas/patologia , Neoplasias Ovarianas/cirurgia , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Feminino , Preservação da Fertilidade/métodos , Procedimentos Cirúrgicos em Ginecologia/métodos , Humanos , Histerectomia/métodos , Laparoscopia/métodos , Laparotomia/métodos , Pessoa de Meia-Idade , Estadiamento de Neoplasias , Reoperação , Estudos Retrospectivos , Salpingo-Ooforectomia/métodos , Adulto Jovem
3.
Int J Gynaecol Obstet ; 72(2): 135-43, 2001 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-11166746

RESUMO

OBJECTIVE: To compare an innovative cesarean section based on Joel-Cohen incision with the traditional Pfannenstiel technique in terms of operative data and post-operative recovery. METHOD: Out of 158 randomized patients, 83 patients underwent the innovative cesarean section (Joel-Cohen incision, one-layer locked uterine suture, no peritoneization) and 75 the traditional operative approach (Pfannenstiel incision, double layer closure of the uterus, visceral and parietal peritoneization). Operative data and post-operative morbidity were compared; sample size was calculated to detect a 13% difference in the occurrence of post-operative fever with a statistical power of 80%. RESULT: Post-operative fever was not different in the two groups. Total operating time was shorter with the innovative technique: 31.6 +/-1.38 min vs. 44.4+/-1.44 (P=0.0001) and fewer sutures were used: 3.6+/-0.13 vs. 6+/-0.13 (P=0.001). Patients operated by the new technique began moving sooner and intestinal function restarted earlier. CONCLUSION: The proposed technique made for shorter operating times and faster recovery but no decrease in puerperal morbidity.


Assuntos
Cesárea/métodos , Peritônio/cirurgia , Infecção da Ferida Cirúrgica/prevenção & controle , Adulto , Análise de Variância , Feminino , Seguimentos , Humanos , Incidência , Morbidade/tendências , Medição da Dor , Gravidez , Probabilidade , Medição de Risco , Sensibilidade e Especificidade , Infecção da Ferida Cirúrgica/epidemiologia , Técnicas de Sutura , Cicatrização/fisiologia
4.
J Hypertens ; 17(12 Pt 2): 1905-10, 1999 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-10703888

RESUMO

OBJECTIVE: Congestive heart failure (CHF) is characterized by sympathetic overactivity but reduced variability of heart interval and sympathetic nerve activity; little information exists, however, about the alterations in blood pressure variability in this syndrome, especially during excitatory manoeuvres such as tilting or exercise. DESIGN AND METHODS: Nine patients with CHF (age 62+/-1 years, NYHA class II-III, ejection fraction 33+/-1%, peak VO2 14.1+/-3.2 ml/min per kg body weight [mean +/- SEM]) and eight healthy control subjects (age 58+/-1 years) with normal left ventricular function were studied. Blood pressure (Finapres), R-R interval (ECG) and respiration (nasal thermistor) were recorded during 15-min periods of supine rest, 70 degree head-up tilting, submaximal bicycling exercise and post-exercise recovery. Total variance and the power of the spectral components of blood pressure (HF, respiratory-related; LF, 0.03-0.14 Hz; and VLF, 0.02-0.003 Hz) were measured. RESULTS: Compared with control subjects, CHF patients have, first, a normal overall blood pressure variability during supine rest but a failure to increase this variability in response to head-up tilt and exercise; second, a suppressed LF spectral component of blood pressure at rest and in response to head-up tilt and exercise; and third, reappearance of LF blood pressure power during postexercise recovery. CONCLUSIONS: In CHF patients, overall blood pressure variability and its LF spectral component are altered at rest and during sympathoexcitatory manoeuvres. Somewhat paradoxically, however, the depressed LF blood pressure power is partially restored during a 15-min recovery period, indicating that at least part of the CHF-related alterations of blood pressure variability have the potential to revert back towards normal under appropriate physiological circumstances.


Assuntos
Pressão Sanguínea , Insuficiência Cardíaca/fisiopatologia , Ciclismo , Frequência Cardíaca , Humanos , Pessoa de Meia-Idade , Valores de Referência , Respiração , Descanso , Decúbito Dorsal , Teste da Mesa Inclinada
5.
Gynecol Oncol ; 61(2): 218-20, 1996 May.
Artigo em Inglês | MEDLINE | ID: mdl-8626136

RESUMO

Careful selection and treatment monitoring of patients with gestational trophoblastic tumors (GTT) is critical because 20 - 50% of patients may develop a resistance and consequently require alternative chemotherapeutic agents. In our study we propose and demonstrate the efficacy of etoposide (VP16) as a second-line drug. An average of 5 courses with VP16 were used to achieve a remission in 12 patients resistant to MTX with low-risk GTT. Toxicity was mild and no resistance to VP16 was observed. A follow-up of 66 months (range, 22-109) has been performed for the patients and all of them are now disease free. Two patients had a pregnancy, respectively, 3 and 4 years after treatment. The others did not desire any pregnancy.


Assuntos
Antimetabólitos Antineoplásicos/uso terapêutico , Antineoplásicos Fitogênicos/uso terapêutico , Etoposídeo/uso terapêutico , Metotrexato/uso terapêutico , Neoplasias Trofoblásticas/tratamento farmacológico , Adolescente , Adulto , Antineoplásicos Fitogênicos/efeitos adversos , Resistência a Medicamentos , Etoposídeo/efeitos adversos , Feminino , Humanos , Pessoa de Meia-Idade , Gravidez , Prognóstico , Resultado do Tratamento
6.
Minerva Ginecol ; 42(7-8): 313-5, 1990.
Artigo em Italiano | MEDLINE | ID: mdl-2293075

RESUMO

The aim of the study was the assessment of the efficacy and safety of Seaprose S in women out patients from the maternity ward with infiltrated surgical wounds subsequent to vaginal birth or caesarean section. The semialkaline proteolithic enzyme Seaprose S, available in 30 mg tablets was administered at a dosage of 3 tablets a day for a period of 8 days. Thirty-two puerpera with a mean age of 31 years +/- 0.9 SE were admitted to the study with an episiotomic wound in 13 cases and a laparotomic wound consequent on caesarean section in the remaining 19 cases. The clinical situation deriving from the surgical wound resolved on average on the 4th day, in particular the swelling and the congestion of the wound had already diminished in the first days of treatment (p less than 0.01). Safety of Seaprose S was good considering that in no cases were side effects attributable to the treatment observed. In conclusion, from the data obtained in this study one may confirm the validity of Seaprose S in the treatment of laparotomic and episiotomic wounds.


Assuntos
Anti-Inflamatórios não Esteroides/uso terapêutico , Ibuprofeno/análogos & derivados , Peptídeo Hidrolases/uso terapêutico , Infecção Puerperal/tratamento farmacológico , Serina Endopeptidases , Adulto , Cesárea , Avaliação de Medicamentos , Episiotomia , Feminino , Guaiacol/análogos & derivados , Humanos , Ibuprofeno/uso terapêutico , Gravidez , Infecção da Ferida Cirúrgica
7.
Thromb Res ; 55(1): 99-107, 1989 Jul 01.
Artigo em Inglês | MEDLINE | ID: mdl-2781523

RESUMO

In order to monitor physiological changes in coagulation and fibrinolysis that occur during normal pregnancy, blood samples were collected in each trimester of pregnancy from 17 volunteers. Control samples were collected from 12 non-pregnant female volunteers. As pregnancy advanced there was a rise in the basal levels of fibrinopeptide A, cross linked D-dimer fragment and the B beta 15-42 fragment and an increase in the in vitro rate of fibrinopeptide A generation. These results were consistent with an increased activation of coagulation during normal pregnancy, compensated for by a concomitant rise in fibrinolytic activity. In two patients who spontaneously aborted, evidence of uncompensated activation of coagulation could be detected before the manifestation of any clinical signs. In a second pregnancy in one of these patients similar changes were observed, but were reversed by heparin treatment and the pregnancy progressed to full-term delivery of a normal infant.


Assuntos
Aborto Espontâneo/etiologia , Coagulação Sanguínea , Fibrinólise , Gravidez/sangue , Aborto Espontâneo/sangue , Testes de Coagulação Sanguínea , Feminino , Produtos de Degradação da Fibrina e do Fibrinogênio/metabolismo , Hemostasia , Heparina/uso terapêutico , Humanos , Complicações Hematológicas na Gravidez/tratamento farmacológico
8.
Ann Ostet Ginecol Med Perinat ; 110(1): 15-9, 1989.
Artigo em Italiano | MEDLINE | ID: mdl-2787970

RESUMO

The authors describe a case of Congenital Hypofibrinogenaemia which was revealed by the haemorrhagic complication occurred immediately after delivery.


Assuntos
Afibrinogenemia/complicações , Hemorragia Pós-Parto/etiologia , Adulto , Afibrinogenemia/congênito , Feminino , Humanos , Gravidez
10.
Eur J Haematol ; 39(5): 467-70, 1987 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-3121382

RESUMO

A 16-yr-old girl with severe von Willebrand disease complicated by the development of precipitating alloantibodies to von Willebrand factor (anti-VWF) had a life-threatening anaphylactoid reaction immediately after the infusion of a commercial plasma concentrate of factor VIII/von Willebrand factor. An early post-infusion activation of the complement system was demonstrated by the appearance of C3 split products and by the drop of serum CH50 activity, occurring in parallel with a post-infusion drop in the anti-VWF antibody levels. Immune complexes remained unchanged in the early post-infusion period and rose to a moderate extent only after 24 h. We conclude that biologically active products of the complement system contributed to the onset of this life-threatening reaction which occurred after concentrate infusion.


Assuntos
Anafilaxia/induzido quimicamente , Isoanticorpos/biossíntese , Doenças de von Willebrand/imunologia , Fator de von Willebrand/efeitos adversos , Adolescente , Complexo Antígeno-Anticorpo/análise , Proteínas do Sistema Complemento/análise , Fator VIII/uso terapêutico , Feminino , Humanos , Doenças de von Willebrand/terapia , Fator de von Willebrand/imunologia , Fator de von Willebrand/uso terapêutico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...